Interpace Biosciences

The company said that it is on track to meet its goal of shaving $7.2 million in costs this year as it undertakes a recently announced restructuring plan.

News items for the in vitro diagnostics industry for the week of Feb. 22, 2021.

The notice was issued due to the company's extended period of non-compliance with the minimum $2.5 million stockholder's equity requirement for continued listing.

Interpace said that the novel monoclonal antibody, Das-1, will provide additional data regarding pancreatic cancer risk to guide personalized patient management. 

News items for the in vitro diagnostics industry for the week of Jan. 25, 2021.

For the three months ended Sept. 30, the firm had total revenues of $8.2 million compared to $7.7 million a year ago.

News items for the in vitro diagnostics industry for the week of Nov. 16, 2020.

For the three months ended June 30, the firm reported revenues of $5.4 million, down from $6.3 million in the year-ago quarter and missing the consensus Wall Street estimate of $5.9 million.

News items for in vitro diagnostics industry for the week of August 17, 2020.

For the three months ended March 31, the firm reported revenues of $9.2 million, up from $6.0 million in the year-ago quarter and beating the consensus Wall Street estimate of $8.9 million.